Skip to content

RNTX RNTX Total Current Liabilities

Total Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$19.16B-20.4%
Gilead Sciences logo
Gilead SciencesGILD
$9.48B-23.2%
AbbVie logo
AbbVieABBV
$42.1B+15.6%
CTO
Citius Oncology, Inc.CTOR
$58.81M+18.2%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$11.7M+9.5%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$19.79M+4.2%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's total current liabilities?
RNTX (RNTX) reported total current liabilities of $13.64M in Q1 2026.
How has RNTX's total current liabilities changed year-over-year?
RNTX's total current liabilities increased by 128.2% year-over-year, from $5.98M to $13.64M.
What is the long-term trend for RNTX's total current liabilities?
Over 5 years (2020 to 2025), RNTX's total current liabilities has grown at a 9.3% compound annual growth rate (CAGR), from $3.96M to $6.18M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.